Mylan wraps up $5.3B Abbott portfolio buyout; Novo raises IPO price on NNIT subsidiary;

@FiercePharma: Oculus leaps into animal health with 6 new skin and eye products. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: FDA problems continue to pile up at Wockhardt Indian plant banned from shipping to the US. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI: Bayer counts on consumer health, pharma growth to power 2015. Story | Follow @CarlyHFierce

> Mylan ($MYL) wrapped up its $5.3 billion buyout of a portfolio of Abbott Laboratories' ($ABT) specialty and branded generics, focused on developed markets outside the U.S.; the deal gives Mylan a new, tax-friendly location in the Netherlands and more heft in international markets. Release

> Novo Nordisk ($NVO) hiked the price range for its planned IPO for the technology services subsidiary NNIT, to 120 to 130 Danish crowns ($18 to $19) from 100 to 120 crowns. Report

> Actavis ($ACT) reportedly has started marketing bonds in a 9-part offering worth as much as $22 billion; the debt sale will finance its buyout of Botox-maker Allergan ($AGN). Report

> The FDA rejected Pacira Pharmaceuticals' application to expand the use of Exparel, a treatment for surgery-related pain, to other nerve-numbing uses. Report

> An Actavis intrauterine device that releases the hormone levonorgestrel, Liletta, won FDA approval to prevent pregnancy for up to three years. Report

> The FDA is requiring additional warnings on multidose diabetes pens, prohibiting patients from sharing the devices, because of the risk of infection. Report

Medical Device News

@FierceMedDev: Startup Akili partners with nonprofit Autism Speaks to test video game. News | Follow @FierceMedDev

@VarunSaxena2: ICYMI: More lawsuits planned as infected endoscope safety scare grows. More | Follow @VarunSaxena2

> J&J confirms $1.9B sale of Cordis unit to Cardinal Health, ending months of speculation. Story

> FDA approves Actavis intrauterine device to prevent pregnancy. Article

> Startup Akili partners with nonprofit Autism Speaks to test video game. More

Biotech News

@FierceBiotech: From FierceDrugDelivery: UPDATED: @US_FDA agrees to review $ENDP's inside-the-cheek pain drug. More | Follow @FierceBiotech

@JohnCFierce: Interested in ADCs and VC cash? Mersana grabs a $35M round, posts ex-Millennium chief Protopapas at helm. Article | Follow @JohnCFierce

@DamianFierce: The fake Immunovaccine release reads like a parody of bio stock pumping. Image | Follow @DamianFierce

> As PhII data looms, Chugai inks a $205M stem cell deal with Athersys. Article

> Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease. Report

> China biotech makes FDA 'breakthrough' for HIV drug. Item

Biotech IT News

> RainDance files for $60M IPO. Item

> Novo Nordisk set to rake in up to $335M from IT unit IPO. Report

> Eccrine bags seed funding for Air Force-developed sweat sensor. News

> Analyst casts doubt on Big Data potential of Covance-LabCorp merger. Story

> H3 hooks up with Foundation Medicine for data-driven oncology R&D. Article

CRO News

> Charles River embraces discovery in management shake-up. News

> Catalent beefs up its European network for clinical supplies. Story

> Enteris gets into contract manufacturing with new plant. Item

> INC Research soars in its first post-IPO quarter. Report

> Icon rides a revenue leap into another growth year. Article

Animal Health News

> Bayer to close animal health plant in St. Joseph, MO; sell-off some product lines. More

> Aratana regains dog lymphoma drug from Lilly for 'great price,' say analysts. Story

> Purina faces lawsuit over dogs allegedly sickened by Beneful. Item

> Oculus leaps into animal health with 6 new skin and eye products. Article

> Parnell records strong sales growth, stays focused on arthritis approval. Report

And Finally... India has tightened up its healthcare budget for 2015-2016, a move that disappointed advocates of improved access to care. Report

Suggested Articles

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.

FDA advisors will question the clinical data and manufacturing for Mesoblast's Ryoncil, a cell therapy for pediatric acute graft vs. host disease.